ライフサイエンスコーパス: inefficacy

1 uld be predictive for discontinuation due to inefficacy.

2 clusive; or indicates either serious risk or inefficacy.

3 hree dimensions of exhaustion, cynicism, and inefficacy.

4 redominantly adverse effects or intervention inefficacy.

5 of mania symptoms and discontinuation due to inefficacy.

6 nslation has been limited by immune response inefficacy.

7 (mostly owing to clinical efficacy [38.2%], inefficacy [26.5%], and ADRs [22.8%]).

8 most common reasons for discontinuation were inefficacy (30%), gastrointestinal symptoms (29%), medic

9 (5.1% versus 8.8%, respectively), or due to inefficacy (5.1% versus 11.7%, respectively).

10 tion of all ISDs owing to clinical efficacy, inefficacy, adverse drug reaction (ADR), and other medic

11 amino acids responsible for the inhibitor's inefficacy against other DENV serotypes.

12 s pathway after discontinuing phase 1 due to inefficacy; all other patients received another second-g

13 atients stopped taking the first drug due to inefficacy and 1,023 stopped the first drug due to toxic

14 t cause for ISD discontinuation, followed by inefficacy and ADRs.

15 entify predictors for discontinuation due to inefficacy and adverse events.

16 rican Americans, whereas perceived treatment inefficacy and lacking trust in physicians were associat

17 Relaxin is contraindicated due to inefficacy and severe renal side effects on discontinuat

18 To overcome the inefficacy and undesirable side effects of current cance

19 n low drug accumulation at the tumor region (inefficacy) and drug-induced severe side effects (toxici

20 nt recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discont

21 One proposed mechanism for phenobarbital inefficacy during neonatal seizures is the reduced abund

22 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two pa

23 d rate of second drug discontinuation due to inefficacy (hazard ratio [HR] 2.7, 95% confidence interv

24 to toxicity (HR 2.3, 95% CI 1.9-2.9) but not inefficacy (HR 1.2, 95% CI 0.8-1.6).

25 sion rates that correlate with the vaccine's inefficacy in developing regions.

26 Conventional therapy shows inefficacy in most cases and thus development of new the

27 ure and function, which may underlie vaccine inefficacy in the developing world.

28 were high (41-59%) and were more common for inefficacy in the placebo patients (71.4%), whereas they

29 ziprasidone had lower discontinuation due to inefficacy (N = 50, n = 14284).

30 nued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than q

31 Further experiments indicate that the inefficacy of antibiotics against coinfection is attribu

32 Considering the inefficacy of available treatments, we propose that dise

33 s substantial ATP equivalents, and (iii) the inefficacy of azole drugs against P. carinii can be expl

34 These data are consistent with the relative inefficacy of BACE1 and anti-Abeta treatments in AD and

35 nhibits Top1mt religation in contrast to the inefficacy of camptothecin on Top1mt.

36 of arrhythmias during a stress test and the inefficacy of catheter ablation procedures may serve as

37 resistance, new pathogens, and the relative inefficacy of current therapy in compromised hosts.

38 instay of arrhythmia treatment; however, the inefficacy of drug treatment and the potential that anti

39 dent factors for increased complications and inefficacy of EUS-guided hepaticogastrostomy.

40 lying mechanisms for the clinically observed inefficacy of glucocorticoids.

41 liver metastasis accurately recapitulate the inefficacy of ICB therapy in patients, whereas the same

42 nexpected practical consequences such as the inefficacy of many MHC class II tetramers in detecting s

43 mutations due to selective interference-the inefficacy of natural selection on non-recombining genom

44 an survival are frustrating reminders of the inefficacy of our current standard of care for patients

45 Inefficacy of pharmacological inhibition of IL-17RA is o

46 t in the face of recent emerging data on the inefficacy of piperacillin-tazobactam for certain organi

47 ing for any rotor loss, and may underlie the inefficacy of ranolazine to terminate PsAF.

48 Together, these data revealed the inefficacy of SOC drugs to target senescent cells in IPF

49 y of the resistant subpopulation, leading to inefficacy of subsequent colistin therapy.

50 n primary glioblastomas and may underlie the inefficacy of targeted therapies in this disease.

51 rowing tumor cells contribute to an eventual inefficacy of therapeutic vaccinations.

52 o treatment, dropouts for any reason and for inefficacy of treatment, and important adverse events.

53 atment, study dropout for any reason and for inefficacy of treatment, use of drugs to treat parkinson

54 ation of treatment because of any cause, and inefficacies or intolerabilities.

55 with migraine discontinue medications due to inefficacy or adverse effects.

56 known only if a study endpoint was reached (inefficacy or adverse events).

57 o patient withdrew from the study because of inefficacy or an adverse event related to pramipexole.

58 scontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reas

59 TNF) drugs do not respond because of primary inefficacy or loss of response.

60 In drug therapy, we face the problems of inefficacy or nonspecific effects; hence, nanosystems ar

61 isk of stopping and the reason for stopping (inefficacy or toxicity).

62 rosis factor (anti-TNF) agent, due to either inefficacy or toxicity, are frequently switched to a sec

63 First drug discontinuation due to inefficacy was associated with an increased rate of seco

64 from criss-cross experiments, the functional inefficacy was not rooted in NOD Tregs, which suppressed

65 was a predictor for "discontinuation due to inefficacy," whereas undifferentiated uveitis was a pred